Skip to main content
single5MG

Thymosin Alpha-1

5MG Protocol

Thymosin Alpha-1 5MG

Injection Freq.

Inject once daily

Cycle Sched.

8–12 weeks; optional extension to 16 weeks

Reconstitution

3.0 mL BAC water

Supports enhanced T-cell function and immune competence
Supports cytokine signaling relevant to antiviral defense (e.g., IFN-α, IL-2)
Strong safety/tolerability profile described in cited studies
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–1300 mcg (0.3 mg)18
2Weeks 2–8500 mcg (0.5 mg)30

Inject once daily

8–12 weeks; optional extension to 16 weeks

The Thymosin Alpha-1 protocol explains an immune-modulating mechanism rooted in thymic peptide biology. Thymosin Alpha-1 (Tα1) is described as enhancing maturation and differentiation of T cells and improving dendritic-cell function—two central components of adaptive immunity. The page also notes that Tα1 can promote production of key immune cytokines, including interferon-α and interleukin-2, which help coordinate antiviral and cell-mediated immune responses. Clinical contexts summarized include investigations in chronic viral infections (hepatitis B/C, HIV) and critical illness, with meta-analytic evidence referenced for improved outcomes in moderate-to-critical COVID-19 populations. The mechanism is presented as strengthening immune competence and response coordination rather than indiscriminately ‘boosting’ immunity. Safety is a major theme: the protocol cites strong tolerability across extended use and reports that the most common adverse event is mild irritation at the injection site.
Mild injection-site irritation (redness/discomfort)
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)